DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
2025 Maxim Growth Summit
Date: October 22, 2025
Location: New York City
Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. to schedule one-on-one meetings with Aytu's management.
Planet MicroCap Showcase: TORONTO 2025
Date: October 22, 2025 - October 23, 2025
Location: Toronto
Presentation Time: 2:30 p.m. Eastern time
Webcast: https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/eV26zB4GZpybjQPU4g6xja
If you would like to schedule one-on-one investor meetings with Aytu's management, and to attend the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub, please register here: REGISTER. Conversely, you can contact Robert Blum of Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. to assist in coordination.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Robert Blum
Lytham Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.59 |
| Daily Change: | 0.17 6.82 |
| Daily Volume: | 287,399 |
| Market Cap: | US$26.340M |
November 13, 2025 October 28, 2025 September 24, 2025 September 23, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
